TRCT
AGL icon

Tower Research Capital (TRC)’s Agilon Health AGL Stock Holding History

Tower Research Capital (TRC)’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Sell
1,600
-552
-26% -$36.2K ﹤0.01% 1815
2026
Q1 		$17K Buy
2,152
+1,092
+103% +$17.7K ﹤0.01% 3593
2025
Q4 		$18.3K Sell
1,060
-318
-23% -$6.17K ﹤0.01% 3163
2025
Q3 		$35.5K Sell
1,378
-105
-7% -$3.97K ﹤0.01% 2790
2025
Q2 		$85.3K Buy
1,483
+1,011
+214% +$81.1K ﹤0.01% 2512
2025
Q1 		$51.1K Buy
472
+49
+12% +$4.26K ﹤0.01% 2217
2024
Q4 		$20.1K Buy
423
+44
+12% +$2.66K ﹤0.01% 3178
2024
Q3 		$37.3K Buy
379
+125
+49% +$16.1K ﹤0.01% 2885
2024
Q2 		$41.5K Buy
254
+178
+234% +$25.4K ﹤0.01% 3234
2024
Q1 		$11.6K Sell
76
-326
-81% -$54.2K ﹤0.01% 3555
2023
Q4 		$126K Sell
402
-544
-58% -$197K ﹤0.01% 2463
2023
Q3 		$420K Buy
946
+653
+223% +$295K 0.01% 969
2023
Q2 		$127K Sell
293
-263
-47% -$148K ﹤0.01% 1890
2023
Q1 		$330K Sell
556
-271
-33% -$152K 0.01% 1083
2022
Q4 		$334K Buy
827
+605
+273% +$284K 0.01% 949
2022
Q3 		$130K Buy
222
+94
+73% +$56.3K ﹤0.01% 2319
2022
Q2 		$70K Sell
128
-64
-33% -$32.4K ﹤0.01% 2571
2022
Q1 		$122K Buy
192
+171
+814% +$88.1K ﹤0.01% 2060
2021
Q4 		$14K Sell
21
-1,132
-98% -$689K ﹤0.01% 4048
2021
Q3 		$756K Buy
1,153
+1,044
+958% +$892K 0.02% 704
2021
Q2 		$110K Buy
+109
New +$95.5K ﹤0.01% 2348

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Tower Research Capital (TRC)'s AGL Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Agilon Health (AGL) stake by 26% in Q2 2026, selling an estimated $36.2K and leaving 1,600 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #1815.

Tower Research Capital (TRC) first reported a position in AGL in Q2 2021 and has held it in 21 quarters since. The position peaked at $756K in Q3 2021. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • Tower Research Capital (TRC) held 1,600 shares of Agilon Health worth $171K as of Q2 2026.
  • Tower Research Capital (TRC) sold 552 Agilon Health shares in Q2 2026, an estimated $36.2K.
  • Agilon Health made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1815 holding.
  • Tower Research Capital (TRC) first reported a position in Agilon Health in Q2 2021 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Agilon Health position peaked at $756K in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.